Allspring Global Investments
YMAB

Allspring Global Investments’s Y-mAbs Therapeutics YMAB Stock Holding History

Allspring Global Investments’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$105 – 2446
2024
Q3 		$105 Buy
+8
New +$101 ﹤0.01% 2424
2024
Q1 		– Sell
-46
Closed -$313 – 2421
2023
Q4 		$313 Sell
46
-6,438
-99% -$37.2K ﹤0.01% 2176
2023
Q3 		$35.3K Hold
6,484
– – ﹤0.01% 2371
2023
Q2 		$44K Sell
6,484
-8,064
-55% -$60.4K ﹤0.01% 2319
2023
Q1 		$72.9K Buy
14,548
+12,849
+756% +$52.5K ﹤0.01% 2158
2022
Q4 		$8.29K Sell
1,699
-38
-2% -$276 ﹤0.01% 2743
2022
Q3 		$25K Sell
1,737
-2,891
-62% -$47.9K ﹤0.01% 2576
2022
Q2 		$70K Sell
4,628
-13,578
-75% -$158K ﹤0.01% 2160
2022
Q1 		$216K Buy
18,206
+3,143
+21% +$32.3K ﹤0.01% 2550
2021
Q4 		$244K Buy
+15,063
New +$322K ﹤0.01% 2582

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments's YMAB Position: Q4 2024 in Review

Allspring Global Investments sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 8 shares — an estimated $105 sold.

Allspring Global Investments first reported a position in YMAB in Q4 2021 and held it in 10 quarters. The position peaked at $244K in Q4 2021. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • Allspring Global Investments reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 8 Y-mAbs Therapeutics shares in Q4 2024, an estimated $105.
  • Allspring Global Investments first reported a position in Y-mAbs Therapeutics in Q4 2021 and held it in 10 quarters.
  • Allspring Global Investments's Y-mAbs Therapeutics position peaked at $244K in Q4 2021.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.